1
|
Vorobev SV, Yanishevskij SN, Emelin AY, Lebedev AA, Lebedev SP, Makarov YN, Usikov AS, Klotchenko SA, Vasin AV. Prospects for the use of graphene-based biological sensors in the early diagnosis of Alzheimer's disease (review of literature). Klin Lab Diagn 2022; 67:5-12. [PMID: 35077063 DOI: 10.51620/0869-2084-2022-67-1-5-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Among the most significant challenges presented to modern medicine is the problem of cognitive disorders. The relevance of her research is determined by the wide spread of disorders of the higher cortical functions, their significant negative impact on the quality of life of patients, as well as high economic costs on the part of the state and the patient's relatives aimed at organizing medical, diagnostic and rehabilitation processes. The main cause of cognitive impairment in the elderly is Alzheimer's disease. Currently, the criteria for the diagnosis of this nosological form have been developed and are widely used in practice. However, it should be noted that their use is most effective if the patient has a detailed clinical picture, at the stage of dementia. In addition, they provide for the study of biomarkers in a number of cases in the cerebrospinal fluid or using positron emission tomography, which presents certain technical difficulties. Especially significant problems arise in the pre-dement stages. This situation dictates the need to search for new promising diagnostic methods that will have high sensitivity and specificity, as well as the possibility of application in the early stages of Alzheimer's disease, including in outpatient settings. The article provides information about modern methods of computer neuroimaging, discusses the research directions of individual biomarkers, and also shows the prospects for using diagnostic test panels developed on the basis of graphene biosensors, taking into account the latest achievements of nanotechnology and their integration into medical science.
Collapse
Affiliation(s)
- S V Vorobev
- Almazov National Medical Research Centre.,Saint-Petersburg State Pediatric Medical University
| | - S N Yanishevskij
- Almazov National Medical Research Centre.,Military Medical Academy named after S.M. Kirov
| | - A Yu Emelin
- Military Medical Academy named after S.M. Kirov
| | - A A Lebedev
- Saint Petersburg National Research University of Information Technologies, Mechanics and Optics.,Ioffe Institute
| | | | - Yu N Makarov
- Saint Petersburg National Research University of Information Technologies, Mechanics and Optics.,Nitride Crystals Group Ltd
| | - A S Usikov
- Saint Petersburg National Research University of Information Technologies, Mechanics and Optics.,Nitride Crystals Group Ltd
| | | | - A V Vasin
- Smorodintsev Research Institute of Influenza.,Institute of Biomedical Systems and Biotechnology, Peter the Great Saint-Petersburg Polytechnic University
| |
Collapse
|
2
|
Turner S, Lazarus R, Marion D, Main KL. Molecular and Diffusion Tensor Imaging Biomarkers of Traumatic Brain Injury: Principles for Investigation and Integration. J Neurotrauma 2021; 38:1762-1782. [PMID: 33446015 DOI: 10.1089/neu.2020.7259] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The last 20 years have seen the advent of new technologies that enhance the diagnosis and prognosis of traumatic brain injury (TBI). There is recognition that TBI affects the brain beyond initial injury, in some cases inciting a progressive neuropathology that leads to chronic impairments. Medical researchers are now searching for biomarkers to detect and monitor this condition. Perhaps the most promising developments are in the biomolecular and neuroimaging domains. Molecular assays can identify proteins indicative of neuronal injury and/or degeneration. Diffusion imaging now allows sensitive evaluations of the brain's cellular microstructure. As the pace of discovery accelerates, it is important to survey the research landscape and identify promising avenues of investigation. In this review, we discuss the potential of molecular and diffusion tensor imaging (DTI) biomarkers in TBI research. Integration of these technologies could advance models of disease prognosis, ultimately improving care. To date, however, few studies have explored relationships between molecular and DTI variables in patients with TBI. Here, we provide a short primer on each technology, review the latest research, and discuss how these biomarkers may be incorporated in future studies.
Collapse
Affiliation(s)
- Stephanie Turner
- Defense and Veterans Brain Injury Center, Silver Spring, Maryland, USA.,General Dynamics Information Technology, Falls Church, Virginia, USA
| | - Rachel Lazarus
- Defense and Veterans Brain Injury Center, Silver Spring, Maryland, USA.,General Dynamics Information Technology, Falls Church, Virginia, USA
| | - Donald Marion
- Defense and Veterans Brain Injury Center, Silver Spring, Maryland, USA.,General Dynamics Information Technology, Falls Church, Virginia, USA
| | - Keith L Main
- Defense and Veterans Brain Injury Center, Silver Spring, Maryland, USA.,General Dynamics Information Technology, Falls Church, Virginia, USA
| |
Collapse
|
3
|
LeBlond E, Smith-Paine J, Narad M, Wade SL, Gardis M, Naresh M, Makoroff K, Rhine T. Understanding the relationship between family functioning and health-related quality of life in very young children with moderate-to-severe TBI. Clin Neuropsychol 2021; 35:868-884. [PMID: 33634733 DOI: 10.1080/13854046.2021.1881163] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Objective: To investigate the relationship of pre-injury and concurrent family functioning with health-related quality of life (HR QoL) following traumatic brain injury (TBI) or orthopedic injury (OI) in very young children. Method: Prospective enrollment of children ages 0-4 years who presented to the emergency department after sustaining either acute TBI or OI. This is a sub-analysis of children who completed at least one post-injury follow-up visit. At time of study enrollment, parents rated pre-injury family functioning (Family Assessment Device-General Functioning Scale) and the child's HR QoL (Pediatric Quality of Life InventoryTM). Family functioning and HR QoL were assessed at one and six months post-injury. Mixed models were used to examine family functioning as a moderator of a child's HR QoL following injury. Results: Data were analyzed for 42 children with TBI and 24 children with OI. For both groups, better pre-injury family functioning was significantly associated with better HR QoL over time. A triple interaction of injury type by time since injury by concurrent family functioning indicated that children with TBI and poor family functioning had significantly worse HR QoL at six months post-injury relative to other groups. Conclusion: Despite a small sample size, current results underscore the importance of family functioning to recovery following early childhood TBI and support the need for continued research and development of interventions to improve outcomes in this population.
Collapse
Affiliation(s)
- Elizabeth LeBlond
- Psychology Department, University of Cincinnati, Cincinnati, OH, USA.,Division of Rehabilitation Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Julia Smith-Paine
- Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Megan Narad
- Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.,University of Cincinnati Health, Cincinnati, OH, USA
| | - Shari L Wade
- Psychology Department, University of Cincinnati, Cincinnati, OH, USA.,Division of Rehabilitation Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.,Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Molly Gardis
- University of Cincinnati Health, Cincinnati, OH, USA
| | - Mhadhu Naresh
- Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Kathi Makoroff
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.,Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Tara Rhine
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.,Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| |
Collapse
|
4
|
Chakraborty N, Hammamieh R, Gautam A, Miller SA, Condlin ML, Jett M, Scrimgeour AG. TBI weight-drop model with variable impact heights differentially perturbs hippocampus-cerebellum specific transcriptomic profile. Exp Neurol 2020; 335:113516. [PMID: 33172833 DOI: 10.1016/j.expneurol.2020.113516] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 09/28/2020] [Accepted: 10/21/2020] [Indexed: 01/14/2023]
Abstract
The degree of brain injury is the governing factor for the magnitude of the patient's psycho- and physiological deficits post-injury, and the associated long-term consequences. The present scaling method used to segregate the patients among mild, moderate and severe phases of traumatic brain injury (TBI) has major limitations; however, a more continuous stratification of TBI is still elusive. With the anticipation that differentiating molecular markers could be the backbone of a robust method to triage TBI, we used a modified closed-head injury (CHI) Marmarou model with two impact heights (IH). By definition, IH directly correlates with the impact force causing TBI. In our modified CHI model, the rat skull was fitted with a helmet to permit a diffuse axonal injury. With the frontal cortex as the focal point of injury, the adjacent brain regions (hippocampus, HC and cerebellum, CB) were susceptible to diffuse secondary shock injury. At 8 days post injury (po.i.), rats impacted by 120 cm IH (IH120) took a longer time to find an escape route in the Barnes maze as compared to those impacted by 100 cm IH (IH100). Using a time-resolved interrogation of the transcriptomic landscape of HC and CB tissues, we mined those genes that altered their regulations in correlation with the variable IHs. At 14 days po.i., when all rats demonstrated nearly normal visuomotor performance, the bio-functional analysis suggested an advanced healing mechanism in the HC of IH100 group. In contrast, the HC of IH120 group displayed a delayed healing with evidence of active cell death networks. Combining whole genome rat microarrays with behavioral analysis provided the insight of neuroprotective signals that could be the foundation of the next generation triage for TBI patients.
Collapse
Affiliation(s)
- Nabarun Chakraborty
- Geneva Foundation, Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States of America; Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States of America.
| | - Rasha Hammamieh
- Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States of America
| | - Aarti Gautam
- Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States of America
| | - Stacy-Ann Miller
- Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States of America; ORISE, Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States of America
| | - Michelle L Condlin
- Military Nutrition Division, US Army Research Institute of Environmental Medicine, 10 General Greene Ave, Bldg 42, Natick, MA 01760, United States of America
| | - Marti Jett
- Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States of America
| | - Angus G Scrimgeour
- Military Nutrition Division, US Army Research Institute of Environmental Medicine, 10 General Greene Ave, Bldg 42, Natick, MA 01760, United States of America
| |
Collapse
|
5
|
Lai CQ, Ibrahim H, Abd. Hamid AI, Abdullah MZ, Azman A, Abdullah JM. Detection of Moderate Traumatic Brain Injury from Resting-State Eye-Closed Electroencephalography. COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE 2020; 2020:8923906. [PMID: 32256555 PMCID: PMC7086426 DOI: 10.1155/2020/8923906] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 02/04/2020] [Accepted: 02/13/2020] [Indexed: 11/21/2022]
Abstract
Traumatic brain injury (TBI) is one of the injuries that can bring serious consequences if medical attention has been delayed. Commonly, analysis of computed tomography (CT) or magnetic resonance imaging (MRI) is required to determine the severity of a moderate TBI patient. However, due to the rising number of TBI patients these days, employing the CT scan or MRI scan to every potential patient is not only expensive, but also time consuming. Therefore, in this paper, we investigate the possibility of using electroencephalography (EEG) with computational intelligence as an alternative approach to detect the severity of moderate TBI patients. EEG procedure is much cheaper than CT or MRI. Although EEG does not have high spatial resolutions as compared with CT and MRI, it has high temporal resolutions. The analysis and prediction of moderate TBI from EEG using conventional computational intelligence approaches are tedious as they normally involve complex preprocessing, feature extraction, or feature selection of the signal. Thus, we propose an approach that uses convolutional neural network (CNN) to automatically classify healthy subjects and moderate TBI patients. The input to this computational intelligence system is the resting-state eye-closed EEG, without undergoing preprocessing and feature selection. The EEG dataset used includes 15 healthy volunteers and 15 moderate TBI patients, which is acquired at the Hospital Universiti Sains Malaysia, Kelantan, Malaysia. The performance of the proposed method has been compared with four other existing methods. With the average classification accuracy of 72.46%, the proposed method outperforms the other four methods. This result indicates that the proposed method has the potential to be used as a preliminary screening for moderate TBI, for selection of the patients for further diagnosis and treatment planning.
Collapse
Affiliation(s)
- Chi Qin Lai
- School of Electrical and Electronic Engineering, Engineering Campus, Universiti Sains Malaysia, 14300, Nibong Tebal, Penang, Malaysia
| | - Haidi Ibrahim
- School of Electrical and Electronic Engineering, Engineering Campus, Universiti Sains Malaysia, 14300, Nibong Tebal, Penang, Malaysia
| | - Aini Ismafairus Abd. Hamid
- Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kota Bharu, Kelantan, Malaysia
| | - Mohd Zaid Abdullah
- School of Electrical and Electronic Engineering, Engineering Campus, Universiti Sains Malaysia, 14300, Nibong Tebal, Penang, Malaysia
| | - Azlinda Azman
- School of Social Sciences, Universiti Sains Malaysia, 11800 Pulau Pinang, Malaysia
| | - Jafri Malin Abdullah
- Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kota Bharu, Kelantan, Malaysia
- Brain and Behaviour Cluster, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kota Bharu, Kelantan, Malaysia
| |
Collapse
|
6
|
Lai CQ, Abdullah MZ, Hamid AIA, Azman A, Abdullah JM, Ibrahim H. Moderate Traumatic Brain Injury Identification from Power Spectral Density of Electroencephalography's Frequency Bands using Support Vector Machine. 2019 IEEE INTERNATIONAL CIRCUITS AND SYSTEMS SYMPOSIUM (ICSYS) 2019. [DOI: 10.1109/icsys47076.2019.8982505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
7
|
Wagner AK, Kumar RG. TBI Rehabilomics Research: Conceptualizing a humoral triad for designing effective rehabilitation interventions. Neuropharmacology 2018; 145:133-144. [PMID: 30222984 DOI: 10.1016/j.neuropharm.2018.09.011] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Revised: 08/14/2018] [Accepted: 09/10/2018] [Indexed: 12/11/2022]
Abstract
Most areas of medicine use biomarkers in some capacity to aid in understanding how personal biology informs clinical care. This article draws upon the Rehabilomics research model as a translational framework for programs of precision rehabilitation and intervention research focused on linking personal biology to treatment response using biopsychosocial constructs that broadly represent function and that can be applied to many clinical populations with disability. The summary applies the Rehabilomics research framework to the population with traumatic brain injury (TBI) and emphasizes a broad vision for biomarker inclusion, beyond typical brain-derived biomarkers, to capture and/or reflect important neurological and non-neurological pathology associated with TBI as a chronic condition. Humoral signaling molecules are explored as important signaling and regulatory drivers of these chronic conditions and their impact on function. Importantly, secondary injury cascades involved in the humoral triad are influenced by the systemic response to TBI and the development of non-neurological organ dysfunction (NNOD). Biomarkers have been successfully leveraged in other medical fields to inform pre-randomization patient selection for clinical trials, however, this practice largely has not been utilized in TBI research. As such, the applicability of the Rehabilomics research model to contemporary clinical trials and comparative effectiveness research designs for neurological and rehabilitation populations is emphasized. Potential points of intervention to modify inflammation, hormonal, or neurotrophic support through rehabilitation interventions are discussed. This article is part of the Special Issue entitled "Novel Treatments for Traumatic Brain Injury".
Collapse
Affiliation(s)
- A K Wagner
- Department of Physical Medicine & Rehabilitation, University of Pittsburgh, USA; Safar Center for Resuscitation Research, University of Pittsburgh, USA; Department of Neuroscience, University of Pittsburgh, USA; Center for Neuroscience, University of Pittsburgh, USA.
| | - R G Kumar
- Department of Physical Medicine & Rehabilitation, University of Pittsburgh, USA; Safar Center for Resuscitation Research, University of Pittsburgh, USA; Department of Epidemiology, University of Pittsburgh, USA
| |
Collapse
|
8
|
Papa L, Robicsek SA, Brophy GM, Wang KKW, Hannay HJ, Heaton S, Schmalfuss I, Gabrielli A, Hayes RL, Robertson CS. Temporal Profile of Microtubule-Associated Protein 2: A Novel Indicator of Diffuse Brain Injury Severity and Early Mortality after Brain Trauma. J Neurotrauma 2017; 35:32-40. [PMID: 28895474 DOI: 10.1089/neu.2017.4994] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
This study compared cerebrospinal fluid (CSF) levels of microtubule-associated protein 2 (MAP-2) from adult patients with severe traumatic brain injury (TBI) with uninjured controls over 10 days, and examined the relationship between MAP-2 concentrations and acute clinical and radiologic measures of injury severity along with mortality at 2 weeks and over 6 months. This prospective study, conducted at two Level 1 trauma centers, enrolled adults with severe TBI (Glasgow Coma Scale [GCS] score ≤8) requiring a ventriculostomy, as well as controls. Ventricular CSF was sampled from each patient at 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 h following TBI and analyzed via enzyme-linked immunosorbent assay for MAP-2 (ng/mL). Injury severity was assessed by the GCS score, Marshall Classification on computed tomography (CT), Rotterdam CT score, and mortality. There were 151 patients enrolled-130 TBI and 21 control patients. MAP-2 was detectable within 6 h of injury and was significantly elevated compared with controls (p < 0.001) at each time-point. MAP-2 was highest within 72 h of injury and decreased gradually over 10 days. The area under the receiver operating characteristic curve for deciphering TBI versus controls at the earliest time-point CSF was obtained was 0.96 (95% CI 0.93-0.99) and for the maximal 24-h level was 0.98 (95% CI 0.97-1.00). The area under the curve for initial MAP-2 levels predicting 2-week mortality was 0.80 at 6 h, 0.81 at 12 h, 0.75 at 18 h, 0.75 at 24 h, and 0.80 at 48 h. Those with Diffuse Injury III-IV had much higher initial (p = 0.033) and maximal (p = 0.003) MAP-2 levels than those with Diffuse Injury I-II. There was a graded increase in the overall levels and peaks of MAP-2 as the degree of diffuse injury increased within the first 120 h post-injury. These data suggest that early levels of MAP-2 reflect severity of diffuse brain injury and predict 2-week mortality in TBI patients. These findings have implications for counseling families and improving clinical decision making early after injury and guiding multidisciplinary care. Further studies are needed to validate these findings in a larger sample.
Collapse
Affiliation(s)
- Linda Papa
- 1 Department of Emergency Medicine, Orlando Regional Medical Center , Orlando, Florida
| | - Steven A Robicsek
- 2 Department of Anesthesiology, University of Florida , Gainesville, Florida
| | - Gretchen M Brophy
- 3 Department of Pharmacotherapy and Outcomes Science and Neurosurgery, Virginia Commonwealth University , Richmond, Virginia
| | - Kevin K W Wang
- 4 Department of Psychiatry, University of Florida , Gainesville, Florida
| | - H Julia Hannay
- 5 Department of Psychology, University of Houston , Houston, Texas
| | - Shelley Heaton
- 6 Department of Clinical and Health Psychology, University of Florida , Gainesville, Florida
| | - Ilona Schmalfuss
- 7 Department of Radiology, University of Florida , Gainesville, Florida.,8 North Florida/South Georgia Veterans Health System , Gainesville, Florida
| | - Andrea Gabrielli
- 2 Department of Anesthesiology, University of Florida , Gainesville, Florida
| | - Ronald L Hayes
- 9 Banyan Laboratories, Banyan Biomarkers Inc. , Alachua, Florida
| | | |
Collapse
|
9
|
Pandey S, Singh K, Sharma V, Pandey D, Jha RP, Rai SK, Chauhan RS, Singh R. A prospective pilot study on serum cleaved tau protein as a neurological marker in severe traumatic brain injury. Br J Neurosurg 2017; 31:356-363. [PMID: 28293977 DOI: 10.1080/02688697.2017.1297378] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
OBJECTIVE Neurotrauma has been labelled as a "silent epidemic" affecting both the developed and the developing nations. To date, no single brain-specific biomarker has been unanimously accepted for routine clinical use in TBI. Our study aims to determine the correlation of "cleaved-tau protein" in severe traumatic brain injury (TBI) with Glasgow Coma Scale (GCS) at the time of admission, mode of injury, CT findings and outcome at discharge. METHODS The study has been approved by the institutional ethical committee. 40 cases with severe TBI and 40 randomly selected healthy controls were included in this prospective study. Venous blood samples were collected and serum cleaved tau protein levels were measured and correlated with gender, mode of injury, CT findings GCS score and GOS score at discharge. RESULTS In the severe TBI group, the mean serum cleaved tau protein levels in males were 91.65 ± 41.34 pg/ml (mean ± S.D.), and females were 104.43 ± 53.08 pg/ml (mean ± S.D.), (p = 0.27). Mean serum C-tau level in study group was 95.48 ± 44.87 pg/ml (range 36.44-192.34), 95% C.I. (81.13-109.83) and in controls was 33.82 ± 13.65 pg/ml (range 2.48-66.54), 95% C.I. (29.46-38.19) (p < 0.001). The distribution of serum C-tau was in severe TBI group varied in all categories of GCS at 0th day (p < 0.001). Serum cleaved tau protein levels in the good outcome group were 74.26 ± 25.43 pg/ml (mean ± S.D.), range 36.44-144.54, 95% C.I. (63.52-85.00) and the poor-outcome group were 127.32 ± 49.40 pg/ml, range 66.65-192.34, 95% C.I. (100.99-153.64) (p = 0.001). CONCLUSION In severe TBI, serum cleaved tau protein levels were significantly higher as compared to the controls in this prospective study. However, results of this study are preliminary in nature and there is a need to undertake larger prospective studies to reach a definitive conclusion.
Collapse
Affiliation(s)
- Sharad Pandey
- a Department of Neuro Surgery , Sir Sunder Lal Hospital, IMS, BHU , Varanasi , Uttar Pradesh , India
| | - Kulwant Singh
- a Department of Neuro Surgery , Sir Sunder Lal Hospital, IMS, BHU , Varanasi , Uttar Pradesh , India
| | - Vivek Sharma
- a Department of Neuro Surgery , Sir Sunder Lal Hospital, IMS, BHU , Varanasi , Uttar Pradesh , India
| | - Deepa Pandey
- b Department of Clinical Microbiology , Central Hospital DLW , Varanasi , Uttar Pradesh , India
| | - Ravi Prakash Jha
- c Department of Community Medicine, Division of Biostatics , Sir Sunder Lal Hospital, IMS BHU , Varanasi , Uttar Pradesh , India
| | - Sunil Kumar Rai
- d Department of Anatomy , Sir Sunder Lal Hospital, IMS BHU , Varanasi , Uttar Pradesh , India
| | - Richa Singh Chauhan
- e Department of Radio diagnosis , Sir Sunder Lal Hospital, IMS BHU , Varanasi , Uttar Pradesh , India
| | - Royana Singh
- d Department of Anatomy , Sir Sunder Lal Hospital, IMS BHU , Varanasi , Uttar Pradesh , India
| |
Collapse
|
10
|
Thelin EP, Nelson DW, Bellander BM. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien) 2017; 159:209-225. [PMID: 27957604 PMCID: PMC5241347 DOI: 10.1007/s00701-016-3046-3] [Citation(s) in RCA: 174] [Impact Index Per Article: 24.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Accepted: 11/28/2016] [Indexed: 12/12/2022]
Abstract
Background In order to improve injury assessment of brain injuries, protein markers of pathophysiological processes and tissue fate have been introduced in the clinic. The most studied protein “biomarker” of cerebral damage in traumatic brain injury (TBI) is the protein S100B. The aim of this narrative review is to thoroughly analyze the properties and capabilities of this biomarker with focus on clinical utility in the assessment of patients suffering from TBI. Results S100B has successfully been implemented in the clinic regionally (1) to screen mild TBI patients evaluating the need to perform a head computerized tomography, (2) to predict outcome in moderate-to-severe TBI patients, (3) to detect secondary injury development in brain-injured patients and (4) to evaluate treatment efficacy. The potential opportunities and pitfalls of S100B in the different areas usually refer to its specificity and sensitivity to detect and assess intracranial injury. Conclusion Given some shortcomings that should be realized, S100B can be used as a versatile screening, monitoring and prediction tool in the management of TBI patients.
Collapse
Affiliation(s)
- Eric Peter Thelin
- Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Neurosurgical Research Laboratory, Karolinska University Hospital, Building R2:02, S-171 76, Stockholm, Sweden.
| | - David W Nelson
- Division of Perioperative Medicine and Intensive Care (PMI), Section Neuro, Karolinska University Hospital, Stockholm, Sweden
- Department of Physiology and Pharmacology, Section of Anesthesiology and Intensive Care, Karolinska Institutet, Stockholm, Sweden
| | - Bo-Michael Bellander
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
11
|
Thelin EP, Nelson DW, Bellander BM. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien) 2017; 159. [PMID: 27957604 PMCID: PMC5241347 DOI: 10.1007/s00701-016-3046-3;] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
BACKGROUND In order to improve injury assessment of brain injuries, protein markers of pathophysiological processes and tissue fate have been introduced in the clinic. The most studied protein "biomarker" of cerebral damage in traumatic brain injury (TBI) is the protein S100B. The aim of this narrative review is to thoroughly analyze the properties and capabilities of this biomarker with focus on clinical utility in the assessment of patients suffering from TBI. RESULTS S100B has successfully been implemented in the clinic regionally (1) to screen mild TBI patients evaluating the need to perform a head computerized tomography, (2) to predict outcome in moderate-to-severe TBI patients, (3) to detect secondary injury development in brain-injured patients and (4) to evaluate treatment efficacy. The potential opportunities and pitfalls of S100B in the different areas usually refer to its specificity and sensitivity to detect and assess intracranial injury. CONCLUSION Given some shortcomings that should be realized, S100B can be used as a versatile screening, monitoring and prediction tool in the management of TBI patients.
Collapse
Affiliation(s)
- Eric Peter Thelin
- Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Neurosurgical Research Laboratory, Karolinska University Hospital, Building R2:02, S-171 76, Stockholm, Sweden.
| | - David W Nelson
- Division of Perioperative Medicine and Intensive Care (PMI), Section Neuro, Karolinska University Hospital, Stockholm, Sweden
- Department of Physiology and Pharmacology, Section of Anesthesiology and Intensive Care, Karolinska Institutet, Stockholm, Sweden
| | - Bo-Michael Bellander
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
12
|
Graham EM, Burd I, Everett AD, Northington FJ. Blood Biomarkers for Evaluation of Perinatal Encephalopathy. Front Pharmacol 2016; 7:196. [PMID: 27468268 PMCID: PMC4942457 DOI: 10.3389/fphar.2016.00196] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 06/20/2016] [Indexed: 12/17/2022] Open
Abstract
Recent research in identification of brain injury after trauma shows many possible blood biomarkers that may help identify the fetus and neonate with encephalopathy. Traumatic brain injury shares many common features with perinatal hypoxic-ischemic encephalopathy. Trauma has a hypoxic component, and one of the 1st physiologic consequences of moderate-severe traumatic brain injury is apnea. Trauma and hypoxia-ischemia initiate an excitotoxic cascade and free radical injury followed by the inflammatory cascade, producing injury in neurons, glial cells and white matter. Increased excitatory amino acids, lipid peroxidation products, and alteration in microRNAs and inflammatory markers are common to both traumatic brain injury and perinatal encephalopathy. The blood-brain barrier is disrupted in both leading to egress of substances normally only found in the central nervous system. Brain exosomes may represent ideal biomarker containers, as RNA and protein transported within the vesicles are protected from enzymatic degradation. Evaluation of fetal or neonatal brain derived exosomes that cross the blood-brain barrier and circulate peripherally has been referred to as the "liquid brain biopsy." A multiplex of serum biomarkers could improve upon the current imprecise methods of identifying fetal and neonatal brain injury such as fetal heart rate abnormalities, meconium, cord gases at delivery, and Apgar scores. Quantitative biomarker measurements of perinatal brain injury and recovery could lead to operative delivery only in the presence of significant fetal risk, triage to appropriate therapy after birth and measure the effectiveness of treatment.
Collapse
Affiliation(s)
- Ernest M. Graham
- Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of MedicineBaltimore, MD, USA
- Neuroscience Intensive Care Nursery Program, Johns Hopkins University School of MedicineBaltimore, MD, USA
| | - Irina Burd
- Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of MedicineBaltimore, MD, USA
- Neuroscience Intensive Care Nursery Program, Johns Hopkins University School of MedicineBaltimore, MD, USA
- Department of Neurology, Johns Hopkins University School of MedicineBaltimore, MD, USA
- Integrated Research Center for Fetal Medicine, Johns Hopkins University School of MedicineBaltimore, MD, USA
| | - Allen D. Everett
- Neuroscience Intensive Care Nursery Program, Johns Hopkins University School of MedicineBaltimore, MD, USA
- Division of Cardiology, Department of Pediatrics, Johns Hopkins University School of MedicineBaltimore, MD, USA
| | - Frances J. Northington
- Neuroscience Intensive Care Nursery Program, Johns Hopkins University School of MedicineBaltimore, MD, USA
- Division of Neonatology, Department of Pediatrics, Johns Hopkins University School of MedicineBaltimore, MD, USA
| |
Collapse
|
13
|
Mercier E, Boutin A, Shemilt M, Lauzier F, Zarychanski R, Fergusson DA, Moore L, McIntyre LA, Archambault P, Légaré F, Rousseau F, Lamontagne F, Nadeau L, Turgeon AF. Predictive value of neuron-specific enolase for prognosis in patients with moderate or severe traumatic brain injury: a systematic review and meta-analysis. CMAJ Open 2016; 4:E371-E382. [PMID: 27975043 PMCID: PMC5143026 DOI: 10.9778/cmajo.20150061] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Prognosis is difficult to establish early after moderate or severe traumatic brain injury despite representing an important concern for patients, families and medical teams. Biomarkers, such as neuron-specific enolase, have been proposed as potential early prognostic indicators. Our objective was to determine the association between neuron-specific enolase and clinical outcomes, and the prognostic value of neuron-specific enolase after a moderate or severe traumatic brain injury. METHODS We searched MEDLINE, Embase, The Cochrane Library and Biosis Previews, and reviewed reference lists of eligible articles to identify studies. We included cohort studies and randomized controlled trials that evaluated the prognostic value of neuron-specific enolase to predict mortality or Glasgow Outcome Scale score in patients with moderate or severe traumatic brain injury. Two reviewers independently collected data. The pooled mean differences were analyzed using random-effects models. We assessed risk of bias using a customized Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Subgroup and sensitivity analyses were performed based on a priori hypotheses. RESULTS We screened 5026 citations from which 30 studies (involving 1321 participants) met our eligibility criteria. We found a significant positive association between neuron-specific enolase serum levels and mortality (10 studies, n = 474; mean difference [MD] 18.46 µg/L, 95% confidence interval [CI] 10.81 to 26.11 µg/L; I2 = 83%) and a Glasgow Outcome Scale ≤ 3 (14 studies, n = 603; MD 17.25 µg/L, 95% CI 11.42 to 23.07 µg/L; I2 = 82%). We were unable to determine a clinical threshold value using the available patient data. INTERPRETATION In patients with moderate or severe traumatic brain injury, increased neuron-specific enolase serum levels are associated with unfavourable outcomes. The optimal neuron-specific enolase threshold value to predict unfavourable prognosis remains unknown and clinical decision-making is currently not recommended until additional studies are made available.
Collapse
Affiliation(s)
- Eric Mercier
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Amélie Boutin
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Michèle Shemilt
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - François Lauzier
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Ryan Zarychanski
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Dean A Fergusson
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Lynne Moore
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Lauralyn A McIntyre
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Patrick Archambault
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - France Légaré
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - François Rousseau
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - François Lamontagne
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Linda Nadeau
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| | - Alexis F Turgeon
- Centre de recherche du CHU de Québec - Université Laval (Mercier, Boutin, Shemilt, Lauzier, Moore, Archambault, Légaré, Turgeon), Population Health and Optimal Health Practices Research Unit; Department of Social and Preventive Medicine (Boutin, Moore); Department of Anesthesiology and Critical Care Medicine (Lauzier, Archambault, Turgeon), Division of Critical Care Medicine; Department of Family Medicine and Emergency Medicine (Archambault, Légaré), Faculty of Medicine (Lauzier); Department of Molecular Biology (Rousseau, Nadeau), Medical Biochemistry and Pathology, Université Laval, Québec City, Que.; Department of Haematology and Medical Oncology (Zarychanski), University of Manitoba, Winnipeg, Man.; Center for Transfusion and Critical Care Research (Fergusson, McIntyre, Turgeon), Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa; Department of Critical Care Medicine (Fergusson, McIntyre), Ottawa Hospital, University of Ottawa, Ottawa, Ont.; Centre de Recherche Étienne Lebel (Lamontagne), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.; Department of Medicine (Lamontagne), Université de Sherbrooke, Sherbrooke, Que
| |
Collapse
|
14
|
Papa L, Robertson CS, Wang KKW, Brophy GM, Hannay HJ, Heaton S, Schmalfuss I, Gabrielli A, Hayes RL, Robicsek SA. Biomarkers improve clinical outcome predictors of mortality following non-penetrating severe traumatic brain injury. Neurocrit Care 2016; 22:52-64. [PMID: 25052159 DOI: 10.1007/s12028-014-0028-2] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
OBJECTIVE This study assessed whether early levels of biomarkers measured in CSF within 24-h of severe TBI would improve the clinical prediction of 6-months mortality. METHODS This prospective study conducted at two Level 1 Trauma Centers enrolled adults with severe TBI (GCS ≤8) requiring a ventriculostomy as well as control subjects. Ventricular CSF was sampled within 24-h of injury and analyzed for seven candidate biomarkers (UCH-L1, MAP-2, SBDP150, SBDP145, SBDP120, MBP, and S100B). The International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) scores (Core, Extended, and Lab) were calculated for each patient to determine risk of 6-months mortality. The IMPACT models and biomarkers were assessed alone and in combination. RESULTS There were 152 patients enrolled, 131 TBI patients and 21 control patients. Thirty six (27 %) patients did not survive to 6 months. Biomarkers were all significantly elevated in TBI versus controls (p < 0.001). Peak levels of UCH-L1, SBDP145, MAP-2, and MBP were significantly higher in non-survivors (p < 0.05). Of the seven biomarkers measured at 12-h post-injury MAP-2 (p = 0.004), UCH-L1 (p = 0.024), and MBP (p = 0.037) had significant unadjusted hazard ratios. Of the seven biomarkers measured at the earliest time within 24-h, MAP-2 (p = 0.002), UCH-L1 (p = 0.016), MBP (p = 0.021), and SBDP145 (0.029) had the most significant elevations. When the IMPACT Extended Model was combined with the biomarkers, MAP-2 contributed most significantly to the survival models with sensitivities of 97-100 %. CONCLUSIONS These data suggest that early levels of MAP-2 in combination with clinical data provide enhanced prognostic capabilities for mortality at 6 months.
Collapse
Affiliation(s)
- Linda Papa
- Department of Emergency Medicine, Orlando Regional Medical Center, 86 W. Underwood (S-200), Orlando, FL, 32806, USA,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Glushakova OY, Glushakov AV, Miller ER, Valadka AB, Hayes RL. Biomarkers for acute diagnosis and management of stroke in neurointensive care units. Brain Circ 2016; 2:28-47. [PMID: 30276272 PMCID: PMC6126247 DOI: 10.4103/2394-8108.178546] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 02/10/2016] [Accepted: 02/23/2016] [Indexed: 12/11/2022] Open
Abstract
The effectiveness of current management of critically ill stroke patients depends on rapid assessment of the type of stroke, ischemic or hemorrhagic, and on a patient's general clinical status. Thrombolytic therapy with recombinant tissue plasminogen activator (r-tPA) is the only effective treatment for ischemic stroke approved by the Food and Drug Administration (FDA), whereas no treatment has been shown to be effective for hemorrhagic stroke. Furthermore, a narrow therapeutic window and fear of precipitating intracranial hemorrhage by administering r-tPA cause many clinicians to avoid using this treatment. Thus, rapid and objective assessments of stroke type at admission would increase the number of patients with ischemic stroke receiving r-tPA treatment and thereby, improve outcome for many additional stroke patients. Considerable literature suggests that brain-specific protein biomarkers of glial [i.e. S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP)] and neuronal cells [e.g., ubiquitin C-terminal hydrolase-L1 (UCH-L1), neuron-specific enolase (NSE), αII-spectrin breakdown products SBDP120, SBDP145, and SBDP150, myelin basic protein (MBP), neurofilament light chain (NF-L), tau protein, visinin-like protein-1 (VLP 1), NR2 peptide] injury that could be detected in the cerebrospinal fluid (CSF) and peripheral blood might provide valuable and timely diagnostic information for stroke necessary to make prompt management and decisions, especially when the time of stroke onset cannot be determined. This information could include injury severity, prognosis of short-term and long-term outcomes, and discrimination of ischemic or hemorrhagic stroke. This chapter reviews the current status of the development of biomarker-based diagnosis of stroke and its potential application to improve stroke care.
Collapse
Affiliation(s)
- Olena Y Glushakova
- Department of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Alexander V Glushakov
- Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida, USA
- Center for Translational Research in Neurodegenerative Disease, University of Florida College of Medicine, Gainesville, Florida, USA
| | - Emmy R Miller
- Department of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | - Alex B Valadka
- Department of Neurosurgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA
| | | |
Collapse
|
16
|
Assessing bicycle-related trauma using the biomarker S100B reveals a correlation with total injury severity. Eur J Trauma Emerg Surg 2015; 42:617-625. [PMID: 26490563 DOI: 10.1007/s00068-015-0583-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 10/10/2015] [Indexed: 10/22/2022]
Abstract
PURPOSE Worldwide, the use of bicycles, for both recreation and commuting, is increasing. S100B, a suggested protein biomarker for cerebral injury, has been shown to correlate to extracranial injury as well. Using serum levels of S100B, we aimed to investigate how S100B could be used when assessing injuries in patients suffering from bicycle trauma injury. As a secondary aim, we investigated how hospital length of stay and injury severity score (ISS) were correlated to S100B levels. METHODS We performed a retrospective, database study including all patients admitted for bicycle trauma to a level 1 trauma center over a four-year period with admission samples of S100B (n = 127). Computerized tomography (CT) scans were reviewed and remaining data were collected from case records. Univariate- and multivariate regression analyses, linear regressions and comparative statistics (Mann-Whitney) were used where appropriate. RESULTS Both intra- and extracranial injuries were correlated with S100B levels. Stockholm CT score presented the best correlation of an intracranial parameter with S100B levels (p < 0.0001), while the presences of extremity injury, thoracic injury, and non-cervical spinal injury were also significantly correlated (all p < 0.0001, respectively). A multivariate linear regression revealed that Stockholm CT score, non-cervical spinal injury, and abdominal injury all independently correlated with levels of S100B. Patients with a ISS > 15 had higher S100 levels than patients with ISS < 16 (p < 0.0001). Patients with extracranial, as well as intracranial- and extracranial injuries, had significantly higher levels of S100B than patients without injuries (p < 0.05 and p < 0.01, respectively). The admission serum levels of S100B (log, µg/L) were correlated with ISS (log) (r = 0.53) and length of stay (log, days) (r = 0.45). CONCLUSIONS S100B levels were independently correlated with intracranial pathology, but also with the extent of extracranial injury. Length of stay and ISS were both correlated with the admission levels of S100B in bicycle trauma, suggesting S100B to be a good marker of aggregated injury severity. Further studies are warranted to confirm our findings.
Collapse
|
17
|
Li Y, Zhang L, Kallakuri S, Cohen A, Cavanaugh JM. Correlation of mechanical impact responses and biomarker levels: A new model for biomarker evaluation in TBI. J Neurol Sci 2015; 359:280-6. [PMID: 26671128 DOI: 10.1016/j.jns.2015.08.035] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Revised: 08/19/2015] [Accepted: 08/20/2015] [Indexed: 12/19/2022]
Abstract
A modified Marmarou impact acceleration model was used to help screen biomarkers to assess brain injury severity. Anesthetized male Sprague-Dawley rats were subjected to a closed head injury from 1.25, 1.75 and 2.25 m drop heights. Linear and angular responses of the head were measured in vivo. 24h after impact, cerebrospinal fluid (CSF) and serum were collected. CSF and serum levels of phosphorylated neurofilament heavy (pNF-H), glial fibrillary acidic protein (GFAP), interleukin 6 (IL-6), and amyloid beta (Aβ) 1-42 were assessed by enzyme-linked immunosorbent assay (ELISA). Compared to controls, significantly higher CSF and serum pNF-H levels were observed in all impact groups, except between 1.25 m and control in serum. Furthermore, CSF and serum pNF-H levels were significantly different between the impact groups. For GFAP, both CSF and serum levels were significantly higher at 2.25 m compared to 1.75 m, 1.25 m and controls. There was no significant difference in CSF and serum GFAP levels between 1.75 m and 1.25 m, although both groups were significantly higher than control. TBI rats also showed significantly higher levels of IL-6 versus control in both CSF and serum, but no significant difference was observed between each impact group. Levels of Aβ were not significantly different between groups. Pearson's correlation analysis showed pNF-H and GFAP levels in CSF and serum had positive correlation with power (rate of impact energy), followed by average linear acceleration and surface righting (p<0.01), which were good predictors for traumatic axonal injury according to histologic assessment in our previous study, suggesting that they are directly related to the injury mechanism. The model used in this study showed a unique ability in elucidating the relationship between biomarker levels and severity of the mechanical trauma to the brain.
Collapse
Affiliation(s)
- Yan Li
- Department of Biomedical Engineering, Wayne State University, 818 W. Hancock Street, Detroit, MI 48201, United States
| | - Liying Zhang
- Department of Biomedical Engineering, Wayne State University, 818 W. Hancock Street, Detroit, MI 48201, United States.
| | - Srinivasu Kallakuri
- Department of Biomedical Engineering, Wayne State University, 818 W. Hancock Street, Detroit, MI 48201, United States
| | - Abigail Cohen
- Department of Biomedical Engineering, Wayne State University, 818 W. Hancock Street, Detroit, MI 48201, United States
| | - John M Cavanaugh
- Department of Biomedical Engineering, Wayne State University, 818 W. Hancock Street, Detroit, MI 48201, United States
| |
Collapse
|
18
|
S100B and Glial Fibrillary Acidic Protein as Indexes to Monitor Damage Severity in an In Vitro Model of Traumatic Brain Injury. Neurochem Res 2015; 40:991-9. [PMID: 25898931 DOI: 10.1007/s11064-015-1554-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 03/05/2015] [Indexed: 02/06/2023]
Abstract
Traumatic brain injury (TBI) is a leading and rising cause of death and disability worldwide. There is great interest in S100B and Glial Fibrillary Acid Protein (GFAP) as candidate biomarkers of TBI for diagnosis, triage, prognostication and drug development. However, conflicting results especially on S100B hamper their routine application in clinical practice. To try to address this question, we mimicked TBI damage utilizing a well-validated, simplified in vitro model of graded stretch injury induced in rat organotypic hippocampal slice cultures (OHSC). Different severities of trauma, from mild to severe, have been tested by using an equi-biaxial stretch of the OHSCs at a specified Lagrangian strain of 0 (controls), 5, 10, 20 and 50 %. OHSC were analysed at 3, 6, 18, 24, 48 and 96 h post-injury. Cell death, gene expressions and release into the culture medium of S100B and GFAP were determined at each time point. Gene expression and release of S100B slightly increased only in 20 and 50 % stretched OHSC. GFAP over-expression occurred in 10, 20 and 50 % and was inversely correlated with time post-injury. GFAP release significantly increased with time at any level of injury (p < 0.01 with respect to controls). Consequently, the total amount of GFAP released showed a strong linear relationship with the severity of injury (R(2) = 0.7662; p < 0.001). Under these experimental conditions, S100B seems to be useful in diagnosing only moderate to severe TBI-like injuries. Differently, GFAP demonstrates adequate biomarker requisites since its cellular release is affected by all grades of injury severity.
Collapse
|
19
|
Harish G, Mahadevan A, Pruthi N, Sreenivasamurthy SK, Puttamallesh VN, Keshava Prasad TS, Shankar SK, Srinivas Bharath MM. Characterization of traumatic brain injury in human brains reveals distinct cellular and molecular changes in contusion and pericontusion. J Neurochem 2015; 134:156-72. [PMID: 25712633 DOI: 10.1111/jnc.13082] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2014] [Revised: 01/07/2015] [Accepted: 02/19/2015] [Indexed: 12/22/2022]
Abstract
Traumatic brain injury (TBI) contributes to fatalities and neurological disabilities worldwide. While primary injury causes immediate damage, secondary events contribute to long-term neurological defects. Contusions (Ct) are primary injuries correlated with poor clinical prognosis, and can expand leading to delayed neurological deterioration. Pericontusion (PC) (penumbra), the region surrounding Ct, can also expand with edema, increased intracranial pressure, ischemia, and poor clinical outcome. Analysis of Ct and PC can therefore assist in understanding the pathobiology of TBI and its management. This study on human TBI brains noted extensive neuronal, astroglial and inflammatory changes, alterations in mitochondrial, synaptic and oxidative markers, and associated proteomic profile, with distinct differences in Ct and PC. While Ct displayed petechial hemorrhages, thrombosis, inflammation, neuronal pyknosis, and astrogliosis, PC revealed edema, vacuolation of neuropil, axonal loss, and dystrophic changes. Proteomic analysis demonstrated altered immune response, synaptic, and mitochondrial dysfunction, among others, in Ct, while PC displayed altered regulation of neurogenesis and cytoskeletal architecture, among others. TBI brains displayed oxidative damage, glutathione depletion, mitochondrial dysfunction, and loss of synaptic proteins, with these changes being more profound in Ct. We suggest that analysis of markers specific to Ct and PC may be valuable in the evaluation of TBI pathobiology and therapeutics. We have characterized the primary injury in human traumatic brain injury (TBI). Contusions (Ct) - the injury core displayed hemorrhages, inflammation, and astrogliosis, while the surrounding pericontusion (PC) revealed edema, vacuolation, microglial activation, axonal loss, and dystrophy. Proteomic analysis demonstrated altered immune response, synaptic and mitochondrial dysfunction in Ct, and altered regulation of neurogenesis and cytoskeletal architecture in PC. Ct displayed more oxidative damage, mitochondrial, and synaptic dysfunction compared to PC.
Collapse
Affiliation(s)
- Gangadharappa Harish
- Department of Neurochemistry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
| | - Anita Mahadevan
- Department of Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
| | - Nupur Pruthi
- Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
| | | | | | | | - Susarla Krishna Shankar
- Department of Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
| | | |
Collapse
|
20
|
Papa L, Ramia MM, Edwards D, Johnson BD, Slobounov SM. Systematic review of clinical studies examining biomarkers of brain injury in athletes after sports-related concussion. J Neurotrauma 2015; 32:661-73. [PMID: 25254425 DOI: 10.1089/neu.2014.3655] [Citation(s) in RCA: 98] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The aim of this study was to systematically review clinical studies examining biofluid biomarkers of brain injury for concussion in athletes. Data sources included PubMed, MEDLINE, and the Cochrane Database from 1966 to October 2013. Studies were included if they recruited athletes participating in organized sports who experienced concussion or head injury during a sports-related activity and had brain injury biomarkers measured. Acceptable research designs included experimental, observational, and case-control studies. Review articles, opinion papers, and editorials were excluded. After title and abstract screening of potential articles, full texts were independently reviewed to identify articles that met inclusion criteria. A composite evidentiary table was then constructed and documented the study title, design, population, methods, sample size, outcome measures, and results. The search identified 52 publications, of which 13 were selected and critically reviewed. All of the included studies were prospective and were published either in or after the year 2000. Sports included boxing (six studies), soccer (five studies), running/jogging (two studies), hockey (one study), basketball (one study), cycling (one study), and swimming (one study). The majority of studies (92%) had fewer than 100 patients. Three studies (23%) evaluated biomarkers in cerebrospinal fluid (CSF), one in both serum and CSF, and 10 (77%) in serum exclusively. There were 11 different biomarkers assessed, including S100β, glial fibrillary acidic protein, neuron-specific enolase, tau, neurofilament light protein, amyloid beta, brain-derived neurotrophic factor, creatine kinase and heart-type fatty acid binding protein, prolactin, cortisol, and albumin. A handful of biomarkers showed a correlation with number of hits to the head (soccer), acceleration/deceleration forces (jumps, collisions, and falls), postconcussive symptoms, trauma to the body versus the head, and dynamics of different sports. Although there are no validated biomarkers for concussion as yet, there is potential for biomarkers to provide diagnostic, prognostic, and monitoring information postinjury. They could also be combined with neuroimaging to assess injury evolution and recovery.
Collapse
Affiliation(s)
- Linda Papa
- 1 Department of Emergency Medicine, Orlando Regional Medical Center , Orlando, Florida
| | | | | | | | | |
Collapse
|
21
|
Pinelis VG, Sorokina EG, Semenova JB, Karaseva OV, Mescheryakov SV, Chernisheva TA, Arsenieva EN, Roshal LM. Biomarkers in children with traumatic brain injury. Zh Nevrol Psikhiatr Im S S Korsakova 2015; 115:66-72. [DOI: 10.17116/jnevro20151158166-72] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
22
|
Cheng F, Yuan Q, Yang J, Wang W, Liu H. The prognostic value of serum neuron-specific enolase in traumatic brain injury: systematic review and meta-analysis. PLoS One 2014; 9:e106680. [PMID: 25188406 PMCID: PMC4154726 DOI: 10.1371/journal.pone.0106680] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Accepted: 07/30/2014] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Several studies have suggested that neuron-specific enolase (NSE) in serum may be a biomarker of traumatic brain injury. However, whether serum NSE levels correlate with outcomes remains unclear. The purpose of this review was to evaluate the prognostic value of serum NSE protein after traumatic brain injury. METHODS PubMed and Embase were searched for relevant studies published up to October 2013. Full-text publications on the relationship of NSE to TBI were included if the studies concerned patients with closed head injury, NSE levels in serum after injury, and Glasgow Outcome Scale (GOS) or Extended GOS (GOSE) scores or mortality. Study design, inclusion criteria, assay, blood sample collection time, NSE cutoff, sensitivity and specificity of NSE for mortality prediction (if sufficient information was provided to calculate these values), and main outcomes were recorded. RESULTS Sixteen studies were eligible for the current meta-analysis. In the six studies comparing NSE concentrations between TBI patients who died and those who survived, NSE concentrations correlated with mortality (M.D. 0.28, 95% confidence interval (CI), 0.21 to 0.34; I2 55%). In the eight studies evaluating GOS or GOSE, patients with unfavorable outcomes had significantly higher NSE concentrations than those with favorable outcomes (M.D. 0.24, 95% CI, 0.17 to 0.31; I2 64%). From the studies providing sufficient data, the pooled sensitivity and specificity for mortality were 0.79 and 0.50, and 0.72 and 0.66 for unfavorable neurological prognosis, respectively. The areas under the SROC curve (AUC) of NSE concentrations were 0.73 (95% CI, 0.66-0.80) for unfavorable outcome and 0.76 (95% CI, 0.62-0.90) for mortality. CONCLUSIONS Mortality and unfavorable outcome were significantly associated with greater NSE concentrations. In addition, NSE has moderate discriminatory ability to predict mortality and neurological outcome in TBI patients. The optimal discrimination cutoff values and optimal sampling time remain uncertain because of significant variations between studies.
Collapse
Affiliation(s)
- Feng Cheng
- Department of Neurosurgery, The First People's Hospital of Kunshan, affiliated with Jiangsu University, Suzhou, PR China
| | - Qiang Yuan
- Department of Neurosurgery, Huashan Hospital, affiliated to Fudan University, Shanghai, PR China
| | - Jian Yang
- Department of Neurosurgery, The First People's Hospital of Kunshan, affiliated with Jiangsu University, Suzhou, PR China
| | - Wenming Wang
- Department of Neurosurgery, The First People's Hospital of Kunshan, affiliated with Jiangsu University, Suzhou, PR China
| | - Hua Liu
- Department of Neurosurgery, The First People's Hospital of Kunshan, affiliated with Jiangsu University, Suzhou, PR China
- * E-mail:
| |
Collapse
|
23
|
Di Battista AP, Rhind SG, Baker AJ. Application of blood-based biomarkers in human mild traumatic brain injury. Front Neurol 2013; 4:44. [PMID: 23641234 PMCID: PMC3640204 DOI: 10.3389/fneur.2013.00044] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2013] [Accepted: 04/18/2013] [Indexed: 12/12/2022] Open
Abstract
Traumatic Brain Injury (TBI) is a global health concern. The majority of TBI's are mild, yet our ability to diagnose and treat mild traumatic brain injury (mTBI) is lacking. This deficiency results from a variety of issues including the difficulty in interpreting ambiguous clinically presented symptoms, and ineffective imaging techniques. Thus, researchers have begun to explore cellular and molecular based approaches to improve both diagnosis and prognosis. This has been met with a variety of challenges, including difficulty in relating biological markers to current clinical symptoms, and overcoming our lack of fundamental understanding of the pathophysiology of mTBI. However, recent adoption of high throughput technologies and a change in focus from the identification of single to multiple markers has given just optimism to mTBI research. The purpose of this review is to highlight a number of current experimental peripheral blood biomarkers of mTBI, as well as comment on the issues surrounding their clinical application and utility.
Collapse
Affiliation(s)
- Alex P. Di Battista
- Faculty of Medicine, Institute of Medical Science, University of TorontoToronto, ON, Canada
| | - Shawn G. Rhind
- Physiology Group, Individual Behaviour and Performance Section, Defence Research and Development Canada TorontoToronto, ON, Canada
| | - Andrew J. Baker
- Faculty of Medicine, Institute of Medical Science, University of TorontoToronto, ON, Canada
- Department of Anesthesia, University of TorontoToronto, ON, Canada
- Department of Surgery, University of TorontoToronto, ON, Canada
- Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s HospitalToronto, ON, Canada
| |
Collapse
|
24
|
Krach LE, Aldahondo N, Sinner A, Quigley S. Current concepts in the rehabilitation of pediatric traumatic brain injury. CURRENT PHYSICAL MEDICINE AND REHABILITATION REPORTS 2013. [DOI: 10.1007/s40141-013-0007-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Papa L, Ramia MM, Kelly JM, Burks SS, Pawlowicz A, Berger RP. Systematic review of clinical research on biomarkers for pediatric traumatic brain injury. J Neurotrauma 2013; 30:324-38. [PMID: 23078348 DOI: 10.1089/neu.2012.2545] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Abstract The objective was to systematically review the medical literature and comprehensively summarize clinical research performed on biomarkers for pediatric traumatic brain injury (TBI) and to summarize the studies that have assessed serum biomarkers acutely in determining intracranial lesions on CT in children with TBI. The search strategy included a literature search of PubMed,(®) MEDLINE,(®) and the Cochrane Database from 1966 to August 2011, as well as a review of reference lists of identified studies. Search terms used included pediatrics, children, traumatic brain injury, and biomarkers. Any article with biomarkers of traumatic brain injury as a primary focus and containing a pediatric population was included. The search initially identified 167 articles. Of these, 49 met inclusion and exclusion criteria and were critically reviewed. The median sample size was 58 (interquartile range 31-101). The majority of the articles exclusively studied children (36, 74%), and 13 (26%) were studies that included both children and adults in different proportions. There were 99 different biomarkers measured in these 49 studies, and the five most frequently examined biomarkers were S100B (27 studies), neuron-specific enolase (NSE) (15 studies), interleukin (IL)-6 (7 studies), myelin basic protein (MBP) (6 studies), and IL-8 (6 studies). There were six studies that assessed the relationship between serum markers and CT lesions. Two studies found that NSE levels ≥15 ng/mL within 24 h of TBI was associated with intracranial lesions. Four studies using serum S100B were conflicting: two studies found no association with intracranial lesions and two studies found a weak association. The flurry of research in the area over the last decade is encouraging but is limited by small sample sizes, variable practices in sample collection, inconsistent biomarker-related data elements, and disparate outcome measures. Future studies of biomarkers for pediatric TBI will require rigorous and more uniform research methodology, common data elements, and consistent performance measures.
Collapse
Affiliation(s)
- Linda Papa
- Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, FL 32806, USA.
| | | | | | | | | | | |
Collapse
|
26
|
Mercier E, Turgeon AF, Boutin A, Lauzier F, Zarychanski R, Archambault P, Granton J, Lamontagne F, Moore L, Rousseau F, Légaré F, Randell E, Lacroix J, Lapointe J, Fergusson D. Predictive value of neuron-specific enolase following moderate and severe traumatic brain injury: a systematic review and meta-analysis. Crit Care 2012. [PMCID: PMC3363729 DOI: 10.1186/cc10918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
27
|
Abstract
BACKGROUND Efforts to produce definitions and diagnostic standards for mild traumatic brain injury (TBI) have a long and complex history. The diagnosis of TBI must be considered in the larger context of neuropsychiatric diagnosis. A major reconceptualization of diagnosis is now underway in which the classical syndrome conceptualization is being discarded. We address the question, what are the implications of this revision of thinking in the specific context of TBI? METHODS A recent literature on logical structures for neuropsychiatric disorders was reviewed. The symptom pattern of TBI was identified, and a literature survey determined the frequency of these symptom patterns in other disorders and in healthy control populations. RESULTS The frequency of symptom endorsement in populations without a history of TBI can be equal to endorsement frequencies in populations with a history of mild TBI. In some studies, the frequency of symptom endorsement in healthy controls having no history of head injury actually exceeded the endorsement rates in a comparison group with a history mild TBI. CONCLUSION The heterogeneity of this clinical population and their clinical presentations, the absence of a unitary etiology of postinjury deficits, and the complex idiosyncratic time course of the appearance of these deficits argue against the valid implementation of the classical model of diagnosis. In addition, the accepted criteria of diagnostic utility are not satisfied. TBI is not a disease; it is an event. More precisely, TBI is an event or a sequence of events that can, in some instances, lead to a diagnosable neurological or psychiatric disorder.
Collapse
|
28
|
Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg 2012; 72:1335-44. [PMID: 22673263 DOI: 10.1097/ta.0b013e3182491e3d] [Citation(s) in RCA: 150] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
BACKGROUND This study compared early serum levels of ubiquitin C-terminal hydrolase (UCH-L1) from patients with mild and moderate traumatic brain injury (TBI) with uninjured and injured controls and examined their association with traumatic intracranial lesions on computed tomography (CT) scan (CT positive) and the need for neurosurgical intervention (NSI). METHODS This prospective cohort study enrolled adult patients presenting to three tertiary care Level I trauma centers after blunt head trauma with loss of consciousness, amnesia, or disorientation and a Glasgow Coma Scale (GCS) score 9 to 15. Control groups included normal uninjured controls and nonhead injured trauma controls presenting to the emergency department with orthopedic injuries or motor vehicle crash without TBI. Blood samples were obtained in all trauma patients within 4 hours of injury and measured by enzyme-linked immunosorbent assay for UCH-L1 (ng/mL ± standard error of the mean). RESULTS There were 295 patients enrolled, 96 TBI patients (86 with GCS score 13-15 and 10 with GCS score 9-12), and 199 controls (176 uninjured, 16 motor vehicle crash controls, and 7 orthopedic controls). The AUC for distinguishing TBI from uninjured controls was 0.87 (95% confidence interval [CI], 0.82-0.92) and for distinguishing those TBIs with GCS score 15 from controls was AUC 0.87 (95% CI, 0.81-0.93). Mean UCH-L1 levels in patients with CT negative versus CT positive were 0.620 (± 0.254) and 1.618 (± 0.474), respectively (p < 0.001), and the AUC was 0.73 (95% CI, 0.62-0.84). For patients without and with NSI, levels were 0.627 (0.218) versus 2.568 (0.854; p < 0.001), and the AUC was 0.85 (95% CI, 0.76-0.94). CONCLUSION UCH-L1 is detectable in serum within an hour of injury and is associated with measures of injury severity including the GCS score, CT lesions, and NSI. Further study is required to validate these findings before clinical application. LEVEL OF EVIDENCE II, prognostic study.
Collapse
|
29
|
Abstract
Mild traumatic brain injury (TBI) is an unfortunately common occurrence in the elderly. With the growing population of older adults in the United States and globally, strategies that reduce the risk of becoming injured need to be developed, and diagnostic tools and treatments that may benefit this group need to be explored. Particular attention needs to be given to polypharmacy, drug interactions, the use of anticoagulants, safety issues in the living environment, elder abuse, and alcohol consumption. Low-mechanism falls should prompt health care providers to consider the possibility of head injury in elderly patients. Early and tailored management of our seniors following a mild TBI can provide them with the best possible quality of life. This review will discuss the current literature on mild TBI in the older adult, address gaps in research, and discuss the implications for future care of the older TBI patient.
Collapse
|
30
|
Protein Biomarkers for Traumatic and Ischemic Brain Injury: From Bench to Bedside. Transl Stroke Res 2011; 2:455-62. [DOI: 10.1007/s12975-011-0137-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2011] [Revised: 11/07/2011] [Accepted: 11/08/2011] [Indexed: 12/31/2022]
|
31
|
Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, Brophy GM, Demery JA, Dixit NK, Ferguson I, Liu MC, Mo J, Akinyi L, Schmid K, Mondello S, Robertson CS, Tortella FC, Hayes RL, Wang KKW. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 2011; 59:471-83. [PMID: 22071014 DOI: 10.1016/j.annemergmed.2011.08.021] [Citation(s) in RCA: 230] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2011] [Revised: 08/24/2011] [Accepted: 08/30/2011] [Indexed: 10/24/2022]
Abstract
STUDY OBJECTIVE This study examines whether serum levels of glial fibrillary acidic protein breakdown products (GFAP-BDP) are elevated in patients with mild and moderate traumatic brain injury compared with controls and whether they are associated with traumatic intracranial lesions on computed tomography (CT) scan (positive CT result) and with having a neurosurgical intervention. METHODS This prospective cohort study enrolled adult patients presenting to 3 Level I trauma centers after blunt head trauma with loss of consciousness, amnesia, or disorientation and a Glasgow Coma Scale (GCS) score of 9 to 15. Control groups included normal uninjured controls and trauma controls presenting to the emergency department with orthopedic injuries or a motor vehicle crash without traumatic brain injury. Blood samples were obtained in all patients within 4 hours of injury and measured by enzyme-linked immunosorbent assay for GFAP-BDP (nanograms/milliliter). RESULTS Of the 307 patients enrolled, 108 were patients with traumatic brain injury (97 with GCS score 13 to 15 and 11 with GCS score 9 to 12) and 199 were controls (176 normal controls and 16 motor vehicle crash controls and 7 orthopedic controls). Receiver operating characteristic curves demonstrated that early GFAP-BDP levels were able to distinguish patients with traumatic brain injury from uninjured controls with an area under the curve of 0.90 (95% confidence interval [CI] 0.86 to 0.94) and differentiated traumatic brain injury with a GCS score of 15 with an area under the curve of 0.88 (95% CI 0.82 to 0.93). Thirty-two patients with traumatic brain injury (30%) had lesions on CT. The area under these curves for discriminating patients with CT lesions versus those without CT lesions was 0.79 (95% CI 0.69 to 0.89). Moreover, the receiver operating characteristic curve for distinguishing neurosurgical intervention from no neurosurgical intervention yielded an area under the curve of 0.87 (95% CI 0.77 to 0.96). CONCLUSION GFAP-BDP is detectable in serum within an hour of injury and is associated with measures of injury severity, including the GCS score, CT lesions, and neurosurgical intervention. Further study is required to validate these findings before clinical application.
Collapse
Affiliation(s)
- Linda Papa
- Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, FL, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Brophy GM, Mondello S, Papa L, Robicsek SA, Gabrielli A, Tepas J, Buki A, Robertson C, Tortella FC, Hayes RL, Wang KKW. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma 2011; 28:861-70. [PMID: 21309726 DOI: 10.1089/neu.2010.1564] [Citation(s) in RCA: 147] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Ubiquitin C-terminal hydrolase-L1 (UCH-L1) is a neuron-specific enzyme that has been identified as a potential biomarker of traumatic brain injury (TBI). The study objectives were to determine UCH-L1 exposure and kinetic metrics, determine correlations between biofluids, and assess outcome correlations in severe TBI patients. Data were analyzed from a prospective, multicenter study of severe TBI (Glasgow Coma Scale [GCS] score ≤ 8). Cerebrospinal fluid (CSF) and serum data from samples taken every 6 h after injury were analyzed by enzyme-linked immunosorbent assay (ELISA). UCH-L1 CSF and serum data from 59 patients were used to determine biofluid correlations. Serum samples from 86 patients and CSF from 59 patients were used to determine outcome correlations. Exposure and kinetic metrics were evaluated acutely and up to 7 days post-injury and compared to mortality at 3 months. There were significant correlations between UCH-L1 CSF and serum median concentrations (r(s)=0.59, p<0.001), AUC (r(s)=0.3, p=0.027), Tmax (r(s)=0.68, p<0.001), and MRT (r(s)=0.65, p<0.001). Outcome analysis showed significant increases in median serum AUC (2016 versus 265 ng/mL*min, p=0.006), and Cmax (2 versus 0.4 ng/mL, p=0.003), and a shorter Tmax (8 versus 19 h, p=0.04) in those who died versus those who survived, respectively. In the first 24 h after injury, there was a statistically significant acute increase in CSF and serum median Cmax((0-24h)) in those who died. This study shows a significant correlation between UCH-L1 CSF and serum median concentrations and biokinetics in severe TBI patients, and relationships with clinical outcome were detected.
Collapse
Affiliation(s)
- Gretchen M Brophy
- Virginia Commonwealth University, Pharmacotherapy & Outcomes Sciences and Neurosurgery, Richmond, Virginia 23298-0533, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Mondello S, Muller U, Jeromin A, Streeter J, Hayes RL, Wang KKW. Blood-based diagnostics of traumatic brain injuries. Expert Rev Mol Diagn 2011; 11:65-78. [PMID: 21171922 PMCID: PMC3063529 DOI: 10.1586/erm.10.104] [Citation(s) in RCA: 120] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Traumatic brain injury is a major health and socioeconomic problem that affects all societies. However, traditional approaches to the classification of clinical severity are the subject of debate and are being supplemented with structural and functional neuroimaging, as the need for biomarkers that reflect elements of the pathogenetic process is widely recognized. Basic science research and developments in the field of proteomics have greatly advanced our knowledge of the mechanisms involved in damage and have led to the discovery and rapid detection of new biomarkers that were not available previously. However, translating this research for patients' benefits remains a challenge. In this article, we summarize new developments, current knowledge and controversies, focusing on the potential role of these biomarkers as diagnostic, prognostic and monitoring tools of brain-injured patients.
Collapse
Affiliation(s)
- Stefania Mondello
- Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
- University of Florida, FL, USA
| | - Uwe Muller
- Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
| | - Andreas Jeromin
- Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
| | - Jackson Streeter
- Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
| | - Ronald L Hayes
- Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
- University of Florida, FL, USA
| | - Kevin KW Wang
- Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
- University of Florida, FL, USA
| |
Collapse
|
34
|
Halámek J, Windmiller JR, Zhou J, Chuang MC, Santhosh P, Strack G, Arugula MA, Chinnapareddy S, Bocharova V, Wang J, Katz E. Multiplexing of injury codes for the parallel operation of enzyme logic gates. Analyst 2010; 135:2249-59. [PMID: 20617272 DOI: 10.1039/c0an00270d] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The development of a highly parallel enzyme logic sensing concept employing a novel encoding scheme for the determination of multiple pathophysiological conditions is reported. The new concept multiplexes a contingent of enzyme-based logic gates to yield a distinct 'injury code' corresponding to a unique pathophysiological state as prescribed by a truth table. The new concept is illustrated using an array of NAND and AND gates to assess the biomedical significance of numerous biomarker inputs including creatine kinase, lactate dehydrogenase, norepinephrine, glutamate, alanine transaminase, lactate, glucose, glutathione disulfide, and glutathione reductase to assess soft-tissue injury, traumatic brain injury, liver injury, abdominal trauma, hemorrhagic shock, and oxidative stress. Under the optimal conditions, physiological and pathological levels of these biomarkers were detected through either optical or electrochemical techniques by monitoring the level of the outputs generated by each of the six logic gates. By establishing a pathologically meaningful threshold for each logic gate, the absorbance and amperometric assays tendered the diagnosis in a digitally encoded 6-bit word, defined as an 'injury code'. This binary 'injury code' enabled the effective discrimination of 64 unique pathological conditions to offer a comprehensive high-fidelity diagnosis of multiple injury conditions. Such processing of relevant biomarker inputs and the subsequent multiplexing of the logic gate outputs to yield a comprehensive 'injury code' offer significant potential for the rapid and reliable assessment of varied and complex forms of injury in circumstances where access to a clinical laboratory is not viable. While the new concept of parallel and multiplexed enzyme logic gates is illustrated here in connection to multi-injury diagnosis, it could be readily extended to a wide range of practical medical, industrial, security and environmental applications.
Collapse
Affiliation(s)
- Jan Halámek
- Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, Tepas J, Robertson C, Buki A, Scharf D, Jixiang M, Akinyi L, Muller U, Wang KK, Hayes RL. αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma 2010; 27:1203-13. [PMID: 20408766 PMCID: PMC2942904 DOI: 10.1089/neu.2010.1278] [Citation(s) in RCA: 138] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
In this study we assessed the clinical utility of quantitative assessments of alphaII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score 6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.
Collapse
Affiliation(s)
- Stefania Mondello
- Department of Clinical Programs and Center of Innovative Research, and Department of Anesthesiology, University of Florida, Gainesville, Florida
| | - Steven A. Robicsek
- Department of Anesthesiology, University of Florida, Gainesville, Florida
| | - Andrea Gabrielli
- Department of Anesthesiology, University of Florida, Gainesville, Florida
| | - Gretchen M. Brophy
- Department of Pharmacy and Neurosurgery, Virginia Commonwealth Universitya, Richmond, Virginia
| | - Linda Papa
- Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, Florida
| | - Joseph Tepas
- Department of Surgery and Pediatrics, University of Florida, Jacksonville, Florida
| | - Claudia Robertson
- Department of Critical Care, Baylor College of Medicine, Houston, Texas
| | - Andras Buki
- Department of Neurosurgery, University of Pécs, Pécs, Hungary
| | - Dancia Scharf
- Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
| | - Mo Jixiang
- Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
| | - Linnet Akinyi
- Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
| | - Uwe Muller
- Department of Research and Development, Banyan Biomarkers Inc., Alachua, Florida
| | - Kevin K.W. Wang
- Center of Innovative Research, Banyan Biomarkers Inc., and University of Florida, Department of Psychiatry, Gainesville, Florida
| | - Ronald L. Hayes
- Department of Clinical Programs, Banyan Biomarkers Inc., and University of Florida, Department of Anesthesiology, Gainesville, Florida
| |
Collapse
|
36
|
Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 2010; 38:138-44. [PMID: 19726976 DOI: 10.1097/ccm.0b013e3181b788ab] [Citation(s) in RCA: 181] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Ubiquitin C-terminal hydrolase (UCH-L1), also called neuronal-specific protein gene product (PGP 9.3), is highly abundant in neurons. To assess the reliability of UCH-L1 as a potential biomarker for traumatic brain injury (TBI) this study compared cerebrospinal fluid (CSF) levels of UCH-L1 from adult patients with severe TBI to uninjured controls; and examined the relationship between levels with severity of injury, complications and functional outcome. DESIGN This study was designed as prospective case control study. PATIENTS This study enrolled 66 patients, 41 with severe TBI, defined by a Glasgow coma scale (GCS) score of < or =8, who underwent intraventricular intracranial pressure monitoring and 25 controls without TBI requiring CSF drainage for other medical reasons. SETTING : Two hospital system level I trauma centers. MEASUREMENTS AND MAIN RESULTS Ventricular CSF was sampled from each patient at 6, 12, 24, 48, 72, 96, 120, 144, and 168 hrs following TBI and analyzed for UCH-L1. Injury severity was assessed by the GCS score, Marshall Classification on computed tomography and a complicated postinjury course. Mortality was assessed at 6 wks and long-term outcome was assessed using the Glasgow outcome score 6 months after injury. TBI patients had significantly elevated CSF levels of UCH-L1 at each time point after injury compared to uninjured controls. Overall mean levels of UCH-L1 in TBI patients was 44.2 ng/mL (+/-7.9) compared with 2.7 ng/mL (+/-0.7) in controls (p <.001). There were significantly higher levels of UCH-L1 in patients with a lower GCS score at 24 hrs, in those with postinjury complications, in those with 6-wk mortality, and in those with a poor 6-month dichotomized Glasgow outcome score. CONCLUSIONS These data suggest that this novel biomarker has the potential to determine injury severity in TBI patients. Further studies are needed to validate these findings in a larger sample.
Collapse
|
37
|
Hayes RL, Robinson G, Muller U, Wang KKW. Translation of neurological biomarkers to clinically relevant platforms. Methods Mol Biol 2009; 566:303-313. [PMID: 20058180 DOI: 10.1007/978-1-59745-562-6_20] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Like proteomics more generally, neuroproteomics has recently been linked to the discovery of biochemical markers of central nervous system (CNS) injury and disease. Although neuroproteomics has enjoyed considerable success in discovery of candidate biomarkers, there are a number of challenges facing investigators interested in developing clinically useful platforms to assess biomarkers for damage to the CNS. These challenges include intrinsic physiological complications such as the blood-brain barrier. Effective translation of biomarkers to clinical practice also requires development of entirely novel pathways and product development strategies. Drawing from lessons learned from applications of biomarkers to traumatic brain injury, this study outlines major elements of such a pathway. As with other indications, biomarkers can have three major areas of application: (1) drug development; (2) diagnosis and prognosis; (3) patient management. Translation of CNS biomarkers to practical clinical platforms raises a number of integrated elements. Biomarker discovery and initial selection needs to be integrated at the earliest stages with components that will allow systematic prioritization and triage of biomarker candidates. A number of important criteria need to be considered in selecting clinical biomarker candidates. Development of proof of concept assays and their optimization and validation represent an often overlooked feature of biomarker translational research. Initial assay optimization should confirm that assays can detect biomarkers in relevant clinical samples. Since access to human clinical samples is critical to identification of biomarkers relevant to injury and disease as well as for assay development, design of human clinical validation studies is an important component of translational biomarker research platforms. Although these clinical studies share much in common with clinical trials for assessment of drug therapeutic efficacy, there are a number of considerations unique to these efforts. Finally, platform selection and potential assay commercialization need to be considered. Decisions regarding whether or not to seek FDA approval also significantly influence translational research structures.
Collapse
Affiliation(s)
- Ronald L Hayes
- Clinical Department, Banyan Biomarkers Inc., Alachua, FL, USA.
| | | | | | | |
Collapse
|